trending Market Intelligence /marketintelligence/en/news-insights/trending/7iujj1KHapgdbrOlTWnVww2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Eton Pharmaceuticals seeks US FDA approval of injectable hospital-use drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Eton Pharmaceuticals seeks US FDA approval of injectable hospital-use drug

Eton Pharmaceuticals Inc. submitted an application to the U.S. Food and Drug Administration seeking approval of its experimental, injectable hospital-use product DS-200.

The Deer Park, Ill.-based specialty pharmaceutical company, which launched an IPO in 2018, made a submission under the FDA's rolling review process. Under rolling review, companies can submit completed sections of its new drug application rather than wait for every section of the application to be completed before submission.

DS-200, which has received a fast-track designation from the FDA, is an injectable parenteral nutrition product.

Eton said there are no approved versions of DS-200's molecule in injectable form, but its active ingredient is being supplied in the U.S. market through an unapproved drug product.

The company noted that if DS-200 is approved, the unapproved product will have to exit the market within 12 months, according to FDA guidelines.

Eton CEO Sean Brynjelsen said the company will work with FDA during the review process and simultaneously plan a potential commercial launch of the product.